Drug Profile
GW 824575
Alternative Names: GW824575Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics; Eye disorder therapies
- Mechanism of Action CCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in United Kingdom (PO)
- 15 Mar 2012 Phase-I clinical trials in Age-related macular degeneration in United Kingdom (PO)